타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528) Johnson & Johnson / Legend Biotech·BCMA 29 trials | ||
|---|---|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) | Kymriah (tisagenlecleucel) | Carvykti (ciltacabtagene autoleucel) |
Overview Company | Kite / Gilead | Novartis | Johnson & Johnson / Legend Biotech |
Overview Modality | CGT | CGT | CGT |
Overview Target | CD19 | CD19 | BCMA |
Overview Indication | LBCL, FL | ALL, DLBCL, FL | Relapsed or refractory multiple myeloma |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling | 4-1BB persistence profile | Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs. |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. | downregulation of naïve T-cell-associated genes (SELL and CD28) | BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche. |
Positioning Development positioning | 2L+ | — | 2L+ (originally 4L+) |
Technology Vector | Retrovirus | Lentivirus | Lentiviral |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. | Autologous T cells transduced with lentiviral vector encoding CD19-specific CAR with 4-1BB and CD3ζ signaling domains. Engages CD19+ B cells leading to proliferation and cytotoxicity. | Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion. |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. | CD19; measurable residual disease in ALL. | BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence. |
Toxicology Species | — | Mouse | — |
Toxicology Animal (cat.) | Unknown | Human | — |
Toxicology Major finding | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Toxicology CRS | Grade ≥3 ~13% | CRS ~58–79% in ALL; Grade ≥3 CRS managed with tocilizumab per protocol | CRS in ~95% of CARTITUDE-1 patients, grade ≥3 ~4% |
Clinical Safety signal | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528) Johnson & Johnson / Legend Biotech·BCMA 29 trials | ||
|---|---|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) | Kymriah (tisagenlecleucel) | Carvykti (ciltacabtagene autoleucel) |
Overview Company | Kite / Gilead | Novartis | Johnson & Johnson / Legend Biotech |
Overview Modality | CGT | CGT | CGT |
Overview Target | CD19 | CD19 | BCMA |
Overview Indication | LBCL, FL | ALL, DLBCL, FL | Relapsed or refractory multiple myeloma |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling | 4-1BB persistence profile | Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs. |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. | downregulation of naïve T-cell-associated genes (SELL and CD28) | BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche. |
Positioning Development positioning | 2L+ | — | 2L+ (originally 4L+) |
Technology Vector | Retrovirus | Lentivirus | Lentiviral |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. | Autologous T cells transduced with lentiviral vector encoding CD19-specific CAR with 4-1BB and CD3ζ signaling domains. Engages CD19+ B cells leading to proliferation and cytotoxicity. | Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion. |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. | CD19; measurable residual disease in ALL. | BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence. |
Toxicology Species | — | Mouse | — |
Toxicology Animal (cat.) | Unknown | Human | — |
Toxicology Major finding | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Toxicology CRS | Grade ≥3 ~13% | CRS ~58–79% in ALL; Grade ≥3 CRS managed with tocilizumab per protocol | CRS in ~95% of CARTITUDE-1 patients, grade ≥3 ~4% |
Clinical Safety signal | CRS, ICANS, cytopenias | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교